Future options of anti-angiogenic cancer therapy

作     者：Yihai Cao 

作者机构：Department of MicrobiologyTumor and Cell BiologyKarolinska Institute Department of Medical and Health SciencesLinkoping University Department of Cardiovascular SciencesUniversity of Leicester and NIHR Leicester Cardiovascular Biomedical Research UnitGlenfield Hospital 

出 版 物：《Chinese Journal of Cancer》 (Chinese Journal of Cancer)

年 卷 期：2016年第35卷第2期

页      面：88-96页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported by European Research Council advanced grant ANGIOFAT(Project No.250021) the Swedish Research Council the Swedish Cancer Foundation the Karolinska Institute Foundation the Karolinska Institute Distinguished Professor Award the Torsten Soderberg Foundation the Novo Nordisk Foundation the Knut and Alice Wallenberg Foundation 

主　　题：Angiogenesis, Cancer therapy, Anti-angiogenesis, Vascular endothelial growth factor, Biomarker 

摘      要：In human patients,drugs that block tumor vessel growth are widely used to treat a variety of cancer *** rigorous phase 3 clinical trials have demonstrated significant survival benefits;however,the addition of an anti-angiogenic component to conventional therapeutic modalities has generally produced modest survival benefits for cancer ***,it is unclear why these clinically available drugs targeting the same angiogenic pathways produce dissimilar effects in preclinical models and human *** this article,we discuss possible mechanisms of various anti-angiogenic drugs and the future development of optimized treatment regimens.